[{"id":"2d71fd15-e727-4338-8ce7-c1e33e2ba3b1","acronym":"","url":"https://clinicaltrials.gov/study/NCT04857372","created_at":"2021-09-30T12:52:53.152Z","updated_at":"2024-07-02T16:35:03.740Z","phase":"Phase 1","brief_title":"A Phase I Study of IAG933 in Patients With Advanced Mesothelioma and Other Solid Tumors","source_id_and_acronym":"NCT04857372","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" LATS1 • LATS2","pipe":" | ","alterations":" LATS1 mutation • LATS2 mutation","tags":["LATS1 • LATS2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e LATS1 mutation • LATS2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IAG933"],"overall_status":"Recruiting","enrollment":" Enrollment 156","initiation":"Initiation: 10/21/2021","start_date":" 10/21/2021","primary_txt":" Primary completion: 10/06/2025","primary_completion_date":" 10/06/2025","study_txt":" Completion: 10/06/2025","study_completion_date":" 10/06/2025","last_update_posted":"2024-05-14"},{"id":"80d81649-784d-4aaa-986f-3c25d334fd80","acronym":"","url":"https://clinicaltrials.gov/study/NCT04665206","created_at":"2023-08-24T11:08:27.232Z","updated_at":"2024-07-02T16:35:04.273Z","phase":"Phase 1/2","brief_title":"Study to Evaluate VT3989 in Patients With Metastatic Solid Tumors Enriched for Tumors With NF2 or mNF2 Gene Mutations","source_id_and_acronym":"NCT04665206","lead_sponsor":"Vivace Therapeutics, Inc","biomarkers":" NF2","pipe":" | ","alterations":" NF2 mutation","tags":["NF2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NF2 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e VT3989"],"overall_status":"Recruiting","enrollment":" Enrollment 250","initiation":"Initiation: 03/24/2021","start_date":" 03/24/2021","primary_txt":" Primary completion: 12/24/2026","primary_completion_date":" 12/24/2026","study_txt":" Completion: 06/02/2027","study_completion_date":" 06/02/2027","last_update_posted":"2024-05-13"},{"id":"e0be9b49-8cbc-4688-a452-7aaedd1a1b20","acronym":"","url":"https://clinicaltrials.gov/study/NCT05228015","created_at":"2022-02-12T17:47:53.327Z","updated_at":"2024-07-02T16:35:09.961Z","phase":"Phase 1","brief_title":"Oral TEAD Inhibitor Targeting the Hippo Pathway in Subjects With Advanced Solid Tumors","source_id_and_acronym":"NCT05228015","lead_sponsor":"Ikena Oncology","biomarkers":" YAP1 • TFE3 • CAMTA1 • TAFAZZIN","pipe":" | ","alterations":" TFE3 fusion","tags":["YAP1 • TFE3 • CAMTA1 • TAFAZZIN"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TFE3 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tagrisso (osimertinib) • IK-930"],"overall_status":"Recruiting","enrollment":" Enrollment 198","initiation":"Initiation: 01/07/2022","start_date":" 01/07/2022","primary_txt":" Primary completion: 06/01/2025","primary_completion_date":" 06/01/2025","study_txt":" Completion: 06/01/2025","study_completion_date":" 06/01/2025","last_update_posted":"2024-04-12"},{"id":"f94513c7-17ef-4994-b08f-51b6b5cb561e","acronym":"","url":"https://clinicaltrials.gov/study/NCT05789602","created_at":"2023-03-29T14:03:26.969Z","updated_at":"2024-07-02T16:35:20.284Z","phase":"Phase 1","brief_title":"A Study of BPI-460372 in Advanced Solid Tumor Patients","source_id_and_acronym":"NCT05789602","lead_sponsor":"Betta Pharmaceuticals Co., Ltd.","biomarkers":" LATS1","pipe":" | ","alterations":" LATS1 mutation","tags":["LATS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e LATS1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BPI-460372"],"overall_status":"Recruiting","enrollment":" Enrollment 82","initiation":"Initiation: 04/24/2023","start_date":" 04/24/2023","primary_txt":" Primary completion: 04/17/2025","primary_completion_date":" 04/17/2025","study_txt":" Completion: 04/17/2026","study_completion_date":" 04/17/2026","last_update_posted":"2024-02-08"}]